Susquehanna Fundamental Investments’s Royalty Pharma RPRX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-197,265	Closed	-$7.93M	–	1441
2022 Q3	$7.93M	Buy	+197,265	New	+$8.43M	0.13%	217
2021 Q2	–	Sell	-16,632	Closed	-$725K	–	1762
2021 Q1	$725K	Sell	16,632 -53,008	-76%	-$2.51M	0.01%	1006
2020 Q4	$3.48M	Sell	69,640 -46,960	-40%	-$1.99M	0.06%	449
2020 Q3	$4.91M	Buy	116,600 +81,100	+228%	+$3.48M	0.15%	195
2020 Q2	$1.72M	Buy	+35,500	New	+$1.76M	0.08%	316

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna Fundamental Investments's RPRX Position: Q4 2022 in Review

Susquehanna Fundamental Investments sold out of Royalty Pharma (RPRX) in Q4 2022, closing a stake of 197,265 shares — an estimated $7.93M sold.

Susquehanna Fundamental Investments first reported a position in RPRX in Q2 2020 and held it in 5 quarters. The position peaked at $7.93M in Q3 2022. 336 funds tracked by Wall St. Rank hold RPRX as of Q4 2022.

Susquehanna Fundamental Investments reported no remaining Royalty Pharma position as of Q4 2022 after selling out during the quarter.
Susquehanna Fundamental Investments sold 197,265 Royalty Pharma shares in Q4 2022, an estimated $7.93M.
Susquehanna Fundamental Investments first reported a position in Royalty Pharma in Q2 2020 and held it in 5 quarters.
Susquehanna Fundamental Investments's Royalty Pharma position peaked at $7.93M in Q3 2022.
336 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2022, filed 14 Feb 2023.